Viwit Pharmaceutical Co., Ltd., established in 2006, manufactures pharmaceutical intermediates and active pharmaceutical ingredients with a particular specialization in borane- and boron-based reducing reagents, including borane-dimethyl sulfide, borane-THF, borane-pyridine, and various borane-amine complexes, alongside chiral pyrrolidine, piperidine, and indanyl building blocks. Its finished API portfolio includes aprepitant and fosaprepitant dimeglumine, varenicline tartrate, luliconazole, vildagliptin, and the MRI contrast agents gadobutrol monohydrate and gadolinium meglumine. The company offers CRO, CMO, and CDMO contract manufacturing under OEM, ODM, and own-brand arrangements, and sells across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.
No comments available.
Leave your rating & comment